Search results
Showing 451 to 465 of 1029 results for drug therapy
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults.
Electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer (IPG638)
Evidence-based recommendations on electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer in adults. This involves using a small electrical current to improve the effect of chemotherapy given directly into the bladder.
View recommendations for IPG638Show all sections
This guide gives an overview of the process for developing evidence summaries. Evidence summaries provide advice but do not include recommendations and are not formal NICE guidance
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)
Evidence-based recommendations on lorlatinib (Lorviqua) for previously treated ALK-positive advanced non-small-cell lung cancer in adults.
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (TA766)
Evidence-based recommendations on pembrolizumab (Keytruda) for adjuvant treatment of completely resected stage 3 melanoma in adults.
Evidence-based recommendations on nivolumab (Opdivo) for treating locally advanced unresectable or metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy.
Evidence-based recommendations on ixekizumab (Taltz) for treating axial spondyloarthritis in adults.
This guideline covers the rapid identification and early management of major trauma in pre-hospital and hospital settings, including ambulance services, emergency departments, major trauma centres and trauma units. It aims to reduce deaths and disabilities in people with serious injuries by improving the quality of their immediate care. It does not cover care for people with burns.
Irreversible electroporation for treating renal cancer (IPG443)
Evidence-based recommendations on irreversible electroporation (IRE) for treating renal cancer. This involves using electrical pulses to kill cancer cells, applied directly to the tumour through special needles.
View recommendations for IPG443Show all sections
Sections for IPG443
Evidence-based recommendations on pixantrone (Pixuvri) for treating relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma in adults.
This guideline covers when to offer and discuss caesarean birth, procedural aspects of the operation, and care after caesarean birth. It aims to improve the consistency and quality of care for women and pregnant people who are thinking about having a caesarean birth or have had a caesarean birth in the past and are now pregnant again.
Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)
Evidence-based recommendations on finerenone (Kerendia) for stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults.
HIV testing: increasing uptake among people who may have undiagnosed HIV (NG60)
This guideline covers how to increase the uptake of HIV testing in primary and secondary care, specialist sexual health services and the community. It describes how to plan and deliver services that are tailored to the local prevalence of HIV, promote awareness of HIV testing and increase opportunities to offer testing to people who may have undiagnosed HIV.
Evidence-based recommendations on obecabtagene autoleucel (obe-cel; Aucatzyl) for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in adults.
Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)
Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and imatinib (Glivec) for untreated chronic myeloid leukaemia in adults.